Protocol Ledger

NCT05629208 · Phase II · TERMINATED

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Interventional Phase II clinical trial protocol NCT05629208 sponsored by Gilead Sciences in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-17 Enrollment: 20 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05629208
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)20 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05629208
Protocol FieldVerified Registry Value
NCT IdentifierNCT05629208
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment20 participants (ACTUAL)
Registered Start Date2023-04-17
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI